Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
Yi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People&...
Saved in:
Main Authors: | Li Y, Xie Y, Gong C, Zhao Y, Zhang J, Zhang S, Wang L, Chen S, Hu X, Wang B |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/e1b4f99a21dc4a6780fe74ce220f0b01 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020) -
Metastatic breast cancer: Endocrine therapy landscape reshaped
by: Mohamad Adham Salkeni, et al.
Published: (2017) -
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
by: Yannan Zhao, et al.
Published: (2018) -
Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC
by: Pal K, et al.
Published: (2019) -
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
by: Naiba Nabieva, et al.
Published: (2021)